Brand Name

Megestrol Acetate

View Brand Information
FDA approval date: November 30, 1995
Classification: Progestin
Form: Tablet, Suspension

What is Megestrol Acetate?

Megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome . Limitations of Use Therapy with megestrol acetate oral suspension for weight loss should only be insti‑tuted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. Megestrol acetate oral suspension is not intended for prophylactic use to avoid weight loss. Megestrol acetate oral suspension is a progestin indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome .

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor
A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor
Enrollment Status: Recruiting
Publish Date: June 17, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are: Can the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group? Do participa...

Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.

Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study
Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Behavioral, Drug
Study Phase: Phase 2/Phase 3

Summary: To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

View All Clinical Trials

Related Latest Advances

Use of mirtazapine for appetite stimulation and weight gain in cancer-associated cachexia and anorexia: A systematic review.
Use of mirtazapine for appetite stimulation and weight gain in cancer-associated cachexia and anorexia: A systematic review.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 06, 2026
Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial.
Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial.
Journal: BMJ open
Published: April 03, 2026
Ecophysiological responses of juvenile great scallops (Pecten maximus) exposed to pile driving sound playback.
Ecophysiological responses of juvenile great scallops (Pecten maximus) exposed to pile driving sound playback.
Journal: Marine pollution bulletin
Published: April 01, 2026
View All Latest Advances